By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
The potential for any life sciences-related industry in Turkey can be easily characterized as advanced due to the size of the nation, its sizeable population, and its extensive public and a private healthcare system that was created to provide equitable and accessible healthcare to all of its citizens.
International manufacturers of medical devices have significant production and administrative operations in Turkey, which they mostly use as a hub for access to local markets.
The aim of TTCK in Turkey is to oversee, monitor, and manage the production of drugs, medical equipment, traditional herbal and auxiliary items, innovative therapeutic medical devices, and cosmetics.
On the other hand, the SSI is primarily responsible for implementing social insurance and universal health insurance in Turkey.
The Turkey Medical Devices market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Domestic ability to research, produce, and supply medications and treatments features among the top goals of governments throughout the world, and Turkey is no exception. Covid-19 emphasizes the relevance and weaknesses of healthcare value chains.
In order to encourage research and development (R&D), notably in the fields of pharmaceuticals and medical devices, Ankara is aiming to expand the nation’s current healthcare sector and industrial base.
A global pharmaceutical company with headquarters in Istanbul that is pouring millions of dollars into R&D in an effort to become Turkey’s top manufacturer of biosimilars or biological drugs that are highly similar to drugs that have previously received approval.
Following its clearance as a medical product, Enzymatica’s mouthwash for the common cold will be made available in Turkey. This gives millions of customers access to a new market. Sanofi Consumer Health Care will advertise, sell, and distribute the product in Turkey under one of its own brands.
Following the conclusion of its successful paid pilot project, MedX Health Corp. is happy to announce the signing of a commercial distribution deal with Makromed/Arhan.
According to the pilot’s findings, Turkish health care professionals, including dermatologists and oncologists, have a very high degree of acceptance for the MedX DermSecure Screening Platform.
Given these outstanding outcomes, Makromed and MedX have partnered to distribute SIAscopy, a high-definition image capture device, and DermSecure, a secure cloud-based patient management system that transfers and retains patient data throughout the dermatology assessment process.
